Physician profile
John A Abraham
NPI 1871578351
$127,885.54
in general payments reported to CMS, 2019-2025
24 companies · $11K in 2025
The $11K reported for 2025 was more than what 88% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $13K · 2021: $37K · 2022: $9,819 · 2023: $12K · 2024: $27K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Travel and Lodging: $7,653 · Food and Beverage: $4,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,000.00 |
| Travel and Lodging | $7,652.97 |
| Food and Beverage | $4,933.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osteocentric Technologies, INC. | $63,626.93 | 2019-2025 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Daiichi Sankyo INC. | $56,295.09 | 2019-2022 | |
| Stryker Corporation | $2,942.33 | 2019-2025 | Axsos, Bio4, Gamma |
| Carbofix Orthopedics INC | $2,086.41 | 2019-2025 | |
| Onkos Surgical, INC. | $936.67 | 2019-2025 | Eleos Limb Salvage System |
| Wright Medical Technology, INC. | $637.89 | 2019-2020 | |
| Smith+Nephew, INC. | $417.14 | 2019-2024 | Anthology, Real Intelligence |
| Acera Surgical, INC. | $236.07 | 2024-2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $118.86 | 2019 | |
| Abbvie INC. | $118.14 | 2023 | Vraylar |
| Bone Support INC. | $108.29 | 2021 | |
| Carlsmed, INC. | $60.97 | 2024 | Aprevo |
| Evolution Surgical, INC | $56.88 | 2023 | |
| Wound Management Technologies, INC | $51.33 | 2019 | |
| Acumed LLC | $32.33 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $30.48 | 2025 | Zilretta, Iovera |
| Acadia Pharmaceuticals INC | $22.93 | 2023 | Nuplazid |
| Kerecis Limited | $22.70 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Vertex Pharmaceuticals Incorporated | $20.61 | 2025 | |
| Deciphera Pharmaceuticals INC. | $19.56 | 2025 | Qinlock, Romvimza |
| Innovation Technologies INC | $16.08 | 2025 | Irrisept |
| Boston Scientific Corporation | $15.01 | 2021 | |
| Horizon Therapeutics Plc | $12.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,963,021.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.